Table 1 Baseline characteristics of patients with RA with persistent moderate disease activity
Baseline variable | Biologic naïve (N = 207) | Biologic experienced (N = 188) | |
|---|---|---|---|
Age (years) | 58.5 ± 15.6 | 55.4 ± 14.1 | |
Female | 167 (81) | 153 (81) | |
Ethnicity | White | 140 (70) | 112 (74) |
Black | 33 (17) | 25 (17) | |
Asian | 12 (6) | 6 (4) | |
Mixed | 4 (2) | 3 (2) | |
Other | 9 (5) | 5 (3) | |
Duration of RA (years) | 7.0 ± 9.0 | 21.1 ± 12.0 | |
RF positive | 105 (64) | 131 (80) | |
Anti-CCP positive | 69 (54) | 65 (59) | |
Corticosteroids | 22 (11) | 38 (20) | |
Treatment: Biologic naïve | Monotherapy | 99 (52) | – |
Combination | 89 (47) | – | |
None | 3 (2) | – | |
Treatment: Biologic experienced | DMARD | – | 51 (30) |
Biologic | – | 25 (15) | |
DMARD – biologic | – | 94 (55) | |
DAS28-ESR | 4.0 ± 0.5 | 4.1 ± 0.5 | |
28-TJC | 4.3 ± 4.3 | 4.9 ± 4.2 | |
28-SJC | 2.1 ± 2.8 | 2.7 ± 2.6 | |
PtGA | 50.0 ± 21.8 | 51.0 ± 21.4 | |
ESR | 21.8 ± 16.3 | 20.0 ± 16.1 | |
HAQ-DI | 1.2 ± 0.8 | 1.5 ± 0.7 | |
EQ-5D-3L index | 0.5 ± 0.3 | 0.5 ± 0.3 | |
EQ-5D-3L pain | None | 12 (7) | 8 (4) |
Moderate | 135 (79) | 153 (82) | |
Severe | 23 (14) | 26 (14) | |
EQ-5D-3L anxiety/depression | None | 92 (55) | 91 (49) |
Moderate | 64 (38) | 87 (47) | |
Severe | 12 (7) | 8 (4) | |